Boston, USA-based Albireo Pharma (Nasdaq: ALBO) has released positive top-line results from the Phase III PEDFIC 1 trial of odevixibat.
Shares in the company rose sharply following the announcement and stood more than 50% higher by the close of trading on Tuesday.
Specializing in orphan pediatric liver diseases, Albireo is working on novel bile acid modulators. The firm was founded in Sweden, and was originally spun out of Anglo-Swedish drug major AstraZeneca (LSE: AZN).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze